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Abstract
Human esophageal cancers have been shown to express high levels of epidermal growth factor
receptor (EGFR) and a relationship between high EGFR expression and local advance, the num-
ber of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been
demonstrated. We examined the use of gefitinib, an orally active EGFR-selective tyrosine ki-
nase inhibitor, as a new strategy for treatment of esophageal carcinoma. The effects of gefitinib
were evaluated in monotherapy and in combination with radiotherapy in human esophageal car-
cinoma cell lines. Gefitinib produced a dose-dependent inhibition of cellular proliferation in all
of the 8 esophageal carcinoma cell lines examined, with IC50 values ranging from 5.7 microM to
36.9 microM. In combination, gefitinib and radiotherapy showed a synergistic effect in 2 human
esophageal carcinoma cell lines and an additive effect in 5 cell lines. Western blotting demon-
strated that gefitinib blocked activation of the EGFR-extracellular signal-regulated kinase (Erk)
pathway and the EGFR-phosphoinositide-3 kinase (PI3K)-Akt pathway after irradiation. These
results suggest that further evaluation of EGFR blockade as a treatment for esophageal cancer
should be performed, and that radiotherapy combined with EGFR blockade may enhance the re-
sponse of esophageal carcinoma to therapy.
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n the development of tolerance to irradiation, 
an intracellular phosphorylation cascade start-
ing from auto-phosphorylation of transmembrane 
tyrosine kinase receptors,  and of epidermal growth 
factor receptor (EGFR) or HER-1 in particular,  has 
been recognized as a signaling pathway associated 
with cell survival.  An in vivo study using 9 cancer 
cell lines has demonstrated a negative relationship 
between the expression levels of EGFR and sensitiv-
ity to radiation [1].  Low-dose irradiation in A431 
human vulvar squamous carcinoma cells has been 
shown to lead to autophosphorylation of EGFR and 
activated mitogen-activated protein kinase (MAPK), 
resulting in an induced proliferation response [2].  In 
addition,  apoptosis is increased when MAPK activa-
tion is inhibited by PD98059,  a MAPK kinase (MEK) 
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inhibitor,  following low-dose irradiation in A431 
cells [3],  and PD98059 also shows a radiosensitiz-
ing eﬀ ect in leukemia cells and mammary cancer cell 
lines [4,  5].  A study in prostatic cancer cell lines 
has demonstrated that following irradiation,  the acti-
vated transforming growth factor-alpha (TGF-alpha)-
EGFR-MAPK pathway is inhibited by a neutralizing 
antibody of TGF-alpha,  indicating a radiosensitizing 
eﬀ ect [6].  These results suggest that the radiosensi-
tizing eﬀ ect on cancers caused by inhibition of the 
EGFR-MAPK pathway may have potential in clinical 
practice.  The phosphoinositide-3 kinase (PI3K)-Akt 
is an important anti-apoptosis signaling pathway 
downstream of EGFR.  An immunohistochemical 
study in head and neck cancers has showed a correla-
tion of the phosphorylated Akt level in tissues to the 
eﬃ  cacy of radiotherapy [7].  Irradiation activates 
the PI3K-Akt pathway and produces an anti-apoptotic 
eﬀ ect,  and the radiosensitizing eﬀ ects of Wortmannin 
and LY294002,  which are PI3K inhibitors,  have 
been demonstrated in human melanoma cells,  non-
small cell lung cancer cell lines and human glioblas-
toma cell lines [8ﾝ10].  Given that the MAPK and 
PI3K-Akt pathways led to radiation resistance 
through activation in an EGFR-dependent manner, 
EGFR inhibitors may be promising radiosensitizing 
agents,  and C225,  an anti-EGFR monoclonal anti-
body,  has shown encouraging results regarding the 
treatment of head and neck cancers in combination 
with radiotherapy in a clinical trial [11].
　　EGFR has been found to be highly expressed in 
40ﾝ70ｵ of esophageal carcinomas [12,  13],  and a 
relationship between high EGFR expression and 
local advance,  the number of lymph node metastases, 
life expectancy,  and sensitivity to chemo-radiother-
apy has been demonstrated [14ﾝ17].  Based on these 
observations,  we hypothesized that clinical applica-
tion of geﬁ tinib,  an orally active EGFR-selective 
tyrosine kinase inhibitor,  may provide a new strategy 
for treatment of esophageal carcinoma.  The present 
study is the ﬁ rst to investigate the eﬀ ects of geﬁ tinib 
alone and in combination with radiotherapy in esopha-
geal carcinomas,  and its purpose was to evaluate 
these eﬀ ects in several esophageal carcinoma cell 
lines.
Materials and Methods
　　Drugs and reagents.　 Geﬁ tinib was provided 
by AstraZeneca Pharmaceuticals (London,  United 
Kingdom).  The MEK inhibitor PD98059 and the 
PI3K inhibitor LY294002 were obtained from Alexis 
Corporation (San Diego,  CA,  USA).  All inhibitors 
were dissolved in dimethylsulfoxide (DMSO) (Sigma 
Chemical Co.,  St.  Louis,  MO,  USA) and stored at 
－ 20 °C as stock solutions for use in all the experi-
ments.  Control cells were treated with medium con-
taining an equal volume of DMSO.  HEPES,  EDTA, 
Igepal,  DTT,  phenylmethylsulfonyl ﬂ uoride (PMSF), 
aprotinin,  leupeptin,  sodium ﬂ uoride (NaF),  sodium 
orthovanadate (Na3VO4),  ｹ-glycerophosphate,  sodium 
phosphate (Na2HPO4),  citric acid,  propidium iodide, 
and RNase A were purchased from Sigma Chemical 
Co.  (St.  Louis,  MO,  USA).  Goat polyclonal anti-
EGFR (1005),  goat polyclonal anti-p-EGFR 
(Tyr1173),  anti-HER2,  anti-HER3,  rabbit polyclonal 
anti-ERK1 (K-23),  mouse monoclonal anti-p-ERK 
(E-4) [which speciﬁ cally reacts with ERK1 and 
ERK2 phosphorylated at Tyr-204],  rabbit polyclonal 
anti-cyclin D1 (M-20),  mouse monoclonal anti-p-Tyr 
(PY20),  rabbit polyclonal anti-Akt1/2 (H-136),  and 
rabbit polyclonal anti-Bad (C-20) antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, 
CA,  USA).  We also used rabbit polyclonal anti-
AKT/PKB (pS473) phosphospeciﬁ c antibody,  anti-
human BAD (pS112) phosphospeciﬁ c antibody 
(BioSource International,  Camarillo,  CA,  USA), 
and monoclonal anti-ｹ-actin (clone AC-74) mouse asci-
tes ﬂ uid (Sigma).  Peroxidase-labeled antibodies 
against mouse,  rabbit,  and goat were purchased from 
Amersham (Arlington Heights,  IL,  USA).
　　Cell lines and culture conditions.　 The TE 
series of human esophageal cancer cell lines was 
obtained from the Cancer Cell Repository,  Research 
Institute for Tuberculosis and Cancer,  Tohoku 
University.  These cells were cultured in RPMI1640 
medium with 10ｵ fetal bovine serum (Sigma) at 
37 °C in a 5ｵ CO2 incubator.  All cell lines carried 
p53 mutations [18,  19].
　　Cellular proliferation assay.　 Cancer cells 
were seeded on 96-well plates at a concentration of 
5 × 103 cells/well with complete culture medium,  and 
were allowed to adhere to the plate overnight.  The 
adherent cells were incubated in the presence of vari-
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ous amounts of geﬁ tinib (0.01ﾝ100 µM) for a further 
72 h at 37 °C in 5ｵ CO2.  After the treatment,  an 
MTS assay was performed using a CellTiter 96R 
AQueous One Solution Cell Proliferation Assay 
(Promega,  WI,  USA).  The absorbance of the 
treated samples against the blank control was mea-
sured using an Immuno Mini NJ-2300 (Nalge Nunc 
International K.K.,  NY,  USA).  The wavelength for 
measuring the absorbance of the formazan product 
was 490 nm,  and the reference wavelength was 
700 nm.  The antiproliferative activities of geﬁ tinib 
are shown in terms of IC50 values.  For determination 
of the cytotoxic eﬀ ects of radiation alone,  cancer 
cells were seeded on 96-well plates at a concentration 
of 5 × 103 cells/well and allowed to adhere to the 
plate overnight.  Cancer cells were then irradiated 
with a Hitachi X-ray machine (MBR-1520R) operat-
ing at 150 kV and 15 mA,  with 1.0-mm Al ﬁ ltration, 
a focus-source distance of 30 cm,  and a dose rate of 
0.9 Gy/min.  A total of 10 doses (3,  6,  9,  12,  15, 
18,  21,  24,  27,  and 30 Gy) were used,  and irradia-
tion was performed in air at room temperature. 
Following irradiation,  cancer cells were incubated 
for a further 72 h at 37 °C in 5ｵ CO2,  and an MTS 
assay was then performed.  Dose-response curves 
were obtained for 8 esophageal cancer cell lines and 
the cytotoxic eﬀ ects of the ionizing radiation are 
shown in terms of ED50 values.  Cell proliferation 
assays were performed in 3 wells,  and each experi-
ment was repeated three times.  The eﬀ ects of geﬁ -
tinib and ionizing radiation in combination were 
tested at three diﬀ erent ratios of the geﬁ tinib con-
centration to the radiation dose.  Cancer cells were 
irradiated as described above in the presence of geﬁ -
tinib (geﬁ tinib was added to each well 1 h prior to 
irradiation),  and an MTS assay was performed,  as 
also described above.  The timing of exposure to geﬁ -
tinib (before or after irradiation) is important in the 
investigation of the combination effect. 
Autophosphorylation of EGFR after irradiation has 
been reported to occur very early (only 2 min after 
irradiation),  and we also obtained a similar result in 
a preliminary study [20].  Since the present study 
was performed to analyze the combined eﬀ ects of 
irradiation and inhibition of EGFR signaling by an 
EGFR inhibitor,  for this purpose cells were exposed 
to geﬁ tinib from 1 h before irradiation.  The ratio of 
the geﬁ tinib concentration to the radiation dose is 
also important in the investigation of the combination 
eﬀ ect.  Since sensitivities to geﬁ tinib and irradiation 
vary among the 7 esophageal cancer cell lines in 
which the combination eﬀ ects were investigated,  use 
of a single combination ratio in all the cell lines may 
not be appropriate.  Thus,  the eﬀ ects of 3 combina-
tion ratios of the geﬁ tinib concentration (µM) and 
radiation dose (Gy),  3 : 1,  1 : 1 and 1 : 3,  were evalu-
ated.
　　Combination index (CI) calculations.　 The 
cytotoxic eﬀ ects obtained with the diﬀ erent geﬁ tinib 
/ radiation combinations were analyzed according to 
the Chou and Talalay method,  using Calcusyn soft-
ware (Biosoft,  Cambridge,  UK) [21].  Interactions 
between geﬁ tinib and radiation were assessed by 
means of an automatically computed combination 
index (CI) [22].  CI was determined at 50ｵ and 75
ｵ cell death,  and was deﬁ ned as follows : 
CIA＋B ＝ [(DA/A＋B)/DA]＋[(DB/A＋B)/DB]＋
　　　 ＋[㸧(DA/A＋AB×DB/A＋B)/DADB] 
where 
CIA＋B ＝ CI for a ﬁ xed eﬀ ect (F) of the combina-
tion of cytotoxic A and cytotoxic B.
DA/A＋B ＝ concentration of cytotoxic A in the com-
bination A ＋ B giving an eﬀ ect F.
DB/A＋B ＝ concentration of cytotoxic B in the com-
bination A ＋ B giving an eﬀ ect F.
DA ＝ concentration of cytotoxic A alone giving an 
eﬀ ect F.
DB ＝ concentration of cytotoxic B alone giving an 
eﬀ ect F.
㸧 ＝ parameter with a value of 0 when A and B 
are mutually exclusive and 1 when A and B are 
mutually nonexclusive.
　　The combination index indicates the following 
behavior : synergism,  ＜ 0.8 ; additivity,  ＞ 0.8 and ＜ 
1.2 ; antagonism,  ＞ 1.2 ; slight synergistic and addi-
tive cytotoxic activity for values of 0.8 and 1.2, 
respectively.
　　Western blotting.　 Generally,  cells plated in a 
60-mm dish were used for each sample.  After the 
treatment,  the cells were washed once with ice-cold 
PBS without calcium and lysed by the addition of 
50 µl per dish of ice-cold lysis buﬀ er (50 mM 
HEPES-NaOH (pH 7.4),  250 mM NaCl,  1 mM 
EDTA,  1ｵ Igepal,  1 mM DTT,  1 mM PMSF, 
5 µg/ml aprotinin and leupeptin,  1 mM NaF,  2 mM 
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Na3VO4,  10 mM ｹ-glycerophosphate).  The cells were 
lysed for 20 min on ice and clariﬁ ed by centrifuga-
tion.  Whole cell lysate was heated in 5 × SDS sam-
ple buﬀ er (312.5 mM Tris-HCl (pH 6.8),  50ｵ 
Glycerol,  10ｵ SDS,  25ｵ 2-ME,  0.01ｵ BPB) for 
5 min at 95 °C and then subjected to SDS-PAGE. 
After SDS-PAGE,  the protein was transferred to 
polyvinylidene diﬂ uoride membranes (Hybond-P, 
Amersham Pharmacia Biotech,  Buckinghamshire, 
England) and immunoblotted with appropriate pri-
mary antibodies.  For detection,  the blots were incu-
bated with the appropriate secondary antibodies con-
jugated with horseradish peroxidase and were devel-
oped using the enhanced chemiluminescence plus 
Western blotting detection system (Amersham), 
according to the manufacturer’s instruction.
　　Flow cytometry and TUNEL assay.
Trypsinized cells were pelleted by centrifugation at 
500 g for 5 min at 4 °C and ﬁ xed in 70ｵ ethanol for 
48ﾝ72 h at － 20 °C.  After ﬁ xation,  cells were sus-
pended in 100 µl of phosphate-citrate buﬀ er (0.19 M 
Na2HPO4,  4 mM citric acid) and were incubated for 
30 min at room temperature,  before being resus-
pended in 1 ml of PBS containing 10 µg/ml of prop-
idium iodide and 10 µg/ml of RNase A.  The propid-
ium iodide-stained cell samples were assayed at FL2 
on a FACSCalibur (Beckton Dickinson,  San Jose, 
CA,  USA),  and data analysis was performed with 
CELLQuest software (Beckton Dickinson). 
Instrument quality control was conducted daily to 
monitor ﬂ uorescence intensity,  alignment,  and volt-
age standardizations.  A minimum of 10,000 cells was 
collected in each run.  The cells were selected by 
pulse-area and pulse-width analysis,  and only inte-
grated signals were collected to reject doublets. 
Apoptotic cells were detected by ﬂ uorescence micros-
copy (TUNEL assay) using an In Situ Cell Death 
Detection Kit with Fluorescein (Roche Diagnostics), 
according to the manufacturer’s protocol.
Results
　　Association between HER family expression 
levels in esophageal cancer cell lines and antip-
roliferative eﬀ ects of geﬁ tinib and radiation.
HER family (EGFR,  HER2,  HER3) expression lev-
els in 8 esophageal carcinoma cell lines were ana-
lyzed by Western blotting.  TE-4 cells exhibited the 
highest EGFR expression levels,  followed by TE-8, 
TE-3,  and TE-5 cells (Fig.  1).  Geﬁ tinib showed 
growth-inhibitory activity in all the esophageal carci-
noma cell lines examined,  with IC50 values ranging 
from 5.7 µM in TE-4 cells to 36.9 µM in TE-13 cells 
(Table 1).  A statistically signiﬁ cant linear inverse 
correlation was found between EGFR expression lev-
els and IC50 values in the cell lines (p ＝ 0.033, 
r ＝ － 0.706),  but there was no correlation between 
the expression levels of other HER family members 
and IC50 values.  TE-4 cells were the most radioresis-
tant (ED50 : 32.1 Gy) and TE-10 cells the most radio-
sensitive (ED50 : 11.7 Gy).  A statistically signiﬁ cant 
linear correlation was found between EGFR expres-
sion levels and ED50 values for radiation (p ＝ 0.005, 
r ＝ 0.866),  but there was no correlation between the 
expression levels of other HER family members and 
ED50 values.
　　Combination eﬀ ects of geﬁ tinib and radia-
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Fig. 1　　Expression levels of HER family members (EGFR, 
HER2,  and HER3) in each esophageal carcinoma cell line were 
analyzed by Western blotting.  Each band was analyzed using NIH 
image.  Comparison of protein expression levels among the cell 
lines is based on the ratio of expression of a protein in each cell 
line to that in TE-1 (set equal to 1).  Diﬀ erent levels of EGFR 
expression occurred in the TE series,  with TE-4 cells exhibiting 
the highest EGFR expression levels,  followed by TE-8,  TE-3,  and 
TE-5 cells.  ｹ-Actin levels in each cell line are shown as a control.
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tion. The eﬀ ects of geﬁ tinib and radiotherapy in 
combination were evaluated in 7 esophageal carci-
noma cell lines (TE-1,  -3,  -4,  -5,  -7,  -8,  and 10).  A 
typical dose-response curve is shown in Fig.  2,  and 
examples of the experimental data and CI values at 
50ｵ and 75ｵ cell death are shown in Table 2.  The 
linear correlation coeﬃ  cient,  r,  of the median-eﬀ ect 
plot for the data in Table 2 was reasonably good, 
since an r value above 0.9 is considered acceptable 
for cell culture systems [21].  In this experiment, 
the CI value was accepted only when the r value was 
0.95 or higher at all combination ratios of geﬁ tinib 
and RT (3 : 1,  1 : 1,  and 1 : 3).  The combination 
eﬀ ects were judged using the mean CI value at ED50 
for 2 independent experiments.  Among the 7 esopha-
geal cancer cell lines investigated,  an obvious syner-
gistic eﬀ ect was observed in TE-3 and TE-4 cells, 
while the combination eﬀ ect was additive in the other 
cell lines (Table 3).
　　Eﬀ ects of geﬁ tinib combination treatment 
on intracellular signaling mechanisms follow-
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Fig. 2　　Typical dose-response curves in TE-3 (A) and TE-4 (B) cells.  The ratios of the geﬁ tinib concentration (µM) and radiation dose 
(Gy) were 1 : 1 in both cell lines.  Bars represent means with S.D.  (error bars).
Table 2　　An example of the results : A Combination Index 
experiment in TE-4 cells
Ratio
Geﬁ nitib (µM) :
Radiation (Gy)
Combination Index
Values at r
ED50 ED75
3 : 1 0.22 0.95 0.97
Experiment 1 1 : 1 0.85 0.76 0.97
1 : 3 1.23 1.11 0.98
3 : 1 0.43 0.83 0.98
Experiment 2 1 : 1 0.22 0.43 0.99
1 : 3 0.83 1.05 0.99
Average 0.63 0.85
Geﬁ tinib and radiation were concomitantly administered at ratios of 
geﬁ tinib concentration (µM) to radiation dose (Gy) of 3 : 1,  1 : 1 and 
1 : 3 in each experiment,  and the Combination Index was calcu-
lated using Calcusyn software.  The CI values at ED50 and ED75 
are shown.  The CI value was considered acceptable only when 
the r value was 0.95 or higher for all 3 combination ratios.  The 
mean CI values for 2 experiments are shown in bold letters.
Table 1　　IC50 values of geﬁ tinib and ED50 values of radiation in 
the cell lines
Cell
lines
IC50s mean (s.d.) ED50s mean (s.d.)
Geﬁ tinib (µM) Radiation (Gy)
TE-1 34.7 (1.0) 21.9 (3.2)
TE-3 8.3 (0.1) 15.5 (3.2)
TE-4 5.7 (0.2) 32.1 (7.9)
TE-5 20.8 (3.5) 17.0 (1.8)
TE-7 28.6 (1.5) 17.5 (2.8)
TE-8 9.6 (1.2) 18.4 (2.0)
TE-10 27.1 (0.9) 11.7 (0.7)
TE-13 36.9 (2.2) 13.2 (2.1)
The values shown are the means of 3 independent experiments, 
with the S.D.  given in parentheses.
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ing irradiation.　 Using TE-3 cells,  in which a 
synergistic eﬀ ect of geﬁ tinib and radiation was 
observed,  time-course changes in the intracellular 
EGFR phosphorylation pathway after irradiation and 
the eﬀ ects of the EGFR inhibitor were investigated 
by Western blotting.  Exposure to 1 µM geﬁ tinib 
alone for 1 h inhibited the levels of phosphorylation 
of EGFR and Akt (Fig.  3A).  The EGFR phosphory-
lation level in TE-3 cells was initially elevated 5 min 
after irradiation at 3 Gy,  and then gradually 
increased over 24 h (Fig.  3B).  Phosphorylation of 
Erk,  a representative MAPK,  was observed between 
5 min and 1 h after irradiation,  with this eﬀ ect fol-
lowed by rapid diminution of phosphorylation,  with 
only a slightly elevated phosphorylation level remain-
ing after 24 h.  In accordance with the initial activa-
tion of Erk,  TE-3 cells showed the highest Cyclin 
D1 protein level 12 h after irradiation.  In combina-
tion with geﬁ tinib,  phosphorylation of EGFR and 
30 Acta Med.  Okayama　Vol.  60,  No.  1Taira et al.
Table 3　　Combination Index and eﬀ ects of geﬁ tinib / radiation
Cell
lines
Combination Index Values at
Eﬀ ect
ED50 ED75
TE-1 1.18 1.78 Additive(0.21, 0.95ﾝ1.48) (1.04, 0.93ﾝ2.95)
TE-3 0.35 0.95 Synergistic(0.25, 0.12ﾝ0.71) (0.11, 0.79ﾝ1.01)
TE-4 0.63 0.85 Synergistic(0.41, 0.22ﾝ1.23) (0.25, 0.43ﾝ1.11)
TE-5 1.19 1.13 Additive(0.26, 0.70ﾝ1.39) (0.14, 1.04ﾝ1.37)
TE-7 1.14 0.91 Additive(0.30, 0.79ﾝ1.58) (0.58, 0.41ﾝ1.75)
TE-8 1.06 1.16 Additive(0.25, 0.62ﾝ1.25) (0.41, 0.70ﾝ1.74)
TE-10
0.92 1.40
Additive(0.17, 0.72ﾝ1.19) (0.97, 0.66ﾝ3.26)
The CI values at ED50 and ED75 in the cell lines.  The eﬀ ects were 
judged based on the CI at ED50,  as described in the Methods (S.D., 
range).
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Fig. 3　　A,  Exposure of TE-3 cells to 1 µM geﬁ tinib alone for 1 h resulted in inhibition of phosphorylation of EGFR and Akt ; B,  TE-3 
cells harvested 5 min and 1,  12,  and 24 h after irradiation at a dose of 3 Gy,  with or without treatment with 1 µM geﬁ tinib,  were assayed 
by Western blotting.  In the combination treatment,  the cells were exposed to geﬁ tinib from 1 h before irradiation until harvesting. 
Irradiation resulted in limited phosphorylation of EGFR,  spike-like phosphorylation of Erk1/2,  and an increase in Cyclin D1 after 12 h 
(Lanes 2ﾝ5).  Geﬁ tinib inhibited the activation of EGFR-Erk and the increase in Cyclin D1 (Lanes 6ﾝ9).  Irradiation also induced Akt 
phosphorylation with a peak 5 min to 1 h after irradiation (Lanes 2ﾝ5).  Geﬁ tinib markedly suppressed the Akt phosphorylation (Lanes 6ﾝ9). 
Lane 1 shows the results for untreated controls ; C,  The phosphorylation levels of Bad,  a target of Akt,  were determined 2 and 4 h after 
irradiation.  TE-3 cells showed Bad phosphorylation with a peak 2 h after irradiation (Lanes 2 and 3).  Combination use of geﬁ tinib 
suppressed Bad phosphorylation (Lanes 4 and 5).  Phosphorylation was not suppressed by 10 µM PD98059 (Lanes 6 and 7),  but was 
suppressed by 10 µM LY294002 (Lanes 8 and 9).  Lane 1 shows the results for untreated controls.  Independent experiments performed in 
triplicate gave the same results.
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Erk in TE-3 cells was continuously suppressed,  and 
the Cyclin D1 level was lowest after 12 h,  in con-
trast to the cells exposed to radiation alone.  The 
PI3K-Akt pathway in TE-3 cells was also examined. 
Phosphorylation of Akt started 5 min after irradia-
tion and peaked after 1 h,  but combination treatment 
with geﬁ tinib suppressed phosphorylation of Akt. 
The phosphorylation level of Bad,  which is consid-
ered to be a target factor for Akt,  was elevated from 
2ﾝ4 h after irradiation (Fig.  3 C).  Exposure to geﬁ -
tinib after irradiation suppressed Bad phosphoryla-
tion.  In order to determine whether the PI3K-Akt 
pathway is able to control Bad phosphorylation, 
TE-3 cells were also treated with LY294002 and 
PD98059,  a PI3K inhibitor and a MEK inhibitor, 
respectively.  LY294002 suppressed Bad phosphory-
lation from 2ﾝ4 h after irradiation,  similarly to geﬁ -
tinib,  whereas PD98059 showed no such suppres-
sion.
　　Inhibition of initial mitosis and increased 
apoptosis induced by gefitinib after 
irradiation.　 Analysis of the cell cycle following 
irradiation at 3 Gy showed that TE-3 cells underwent 
a pronounced increase in DNA levels 24 h after irra-
diation,  indicating a G2/M transition,  and then 
returned to a control level of DNA after 48 h (Fig.  4). 
This mitosis after irradiation was inhibited by treat-
ment with geﬁ tinib (1 µM) 3 h after irradiation and by 
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Fig. 4　　TE-3 cells were irradiated at a dose of 3 Gy,  with or without exposure to a drug (geﬁ tinib 1 µM,  PD98059 10 µM,  or LY294002 
10 µM) 3 h after irradiation.  They were then treated with trypsin 24 or 48 h after irradiation to prepare samples for FACS analysis,  as 
described in the Methods.  Inhibition of the G2/M transition after irradiation and a marked increase in the sub-G1 population were 
observed in the geﬁ tinib combination group.  The experiments were performed in triplicate,  and consistent results were obtained.
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Fig. 5　　TE-3 cells were irradiated at a dose of 3 Gy,  with or without exposure to geﬁ tinib (1 µM) 3 h after irradiation.  They were then 
treated with trypsin 48 h after irradiation for use in a TUNEL assay.  Propidium iodide-stained cell samples were assayed at FL2 and 
TUNEL-positive cell samples at FL1.  Treatment with irradiation combined with geﬁ tinib resulted in a signiﬁ cant increase in the number of 
TUNEL-positive cells.
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the MEK inhibitor PD98059 (10 µM),  but not by the 
PI3K inhibitor LY294002 (10 µM).  Based on the 
proportion of apoptotic cells counted as sub-G1 48 h 
after irradiation,  PD98059 and LY294002 slightly 
enhanced the sub-G1 population,  but this eﬀ ect was 
less than that of geﬁ tinib.  In a TUNEL assay,  irra-
diation combined with geﬁ tinib produced a signiﬁ cant 
increase in the number of apoptotic cells (Fig.  5).
Discussion
　　The results of the MTS-1 assays showed that geﬁ -
tinib had an antiproliferative eﬀ ect on all the esopha-
geal carcinoma cell lines examined,  with IC50 values 
ranging from 5.7 µM to 36.9 µM.  The antitumor 
eﬀ ects of geﬁ tinib appear to occur through inhibition 
of signal transduction pathways associated with cell 
growth or apoptosis,  and the existence of abnormal 
signaling that is independent of the EGFR cascade 
could therefore be a possible mechanism through 
which resistance to geﬁ tinib may develop.  Ras muta-
tions occur commonly in tumors and lead to abnormal 
signaling,  but the incidence of a Ras mutation is very 
low in esophageal carcinoma [23,  24].  In light of the 
high expression of EGFR in esophageal carcinoma 
[25],  which implies enhanced signaling activity,  geﬁ -
tinib appears to be appropriate for the clinical treat-
ment of esophageal carcinoma.  The relationship 
between the EGFR expression levels with sensitivity 
to geﬁ tinib is an interesting issue.  Our results indi-
cate a signiﬁ cant correlation between EGFR expres-
sion levels and the IC50 of geﬁ tinib,  suggesting that 
the eﬀ ects of geﬁ tinib may be lessened at lower 
EGFR expression levels.  This ﬁ nding is consistent 
with in vivo studies demonstrating a similar correla-
tion between EGFR gene expression levels with the 
antitumor eﬀ ects of geﬁ tinib in epidermoid carci-
noma,  lung cancer,  and prostatic cancer cell lines 
[26],  and with a study demonstrating a linear 
inverse correlation of EGFR expression levels with 
IC50 values of geﬁ tinib in head and neck cancer and 
colonic cancer cell lines [27].  However,  clinical 
data obtained to date for geﬁ tinib have not demon-
strated any clear relationship between EGFR expres-
sion and geﬁ tinib eﬃ  cacy [28],  although it has 
recently been reported that a mutation in EGFR is 
related to the therapeutic eﬀ ects of geﬁ tinib in lung 
cancer,  which is of interest [29].
　　A relationship between the EGFR signal trans-
duction system and radiosensitivity has been sug-
gested previously.  This signal transduction pathway 
is initiated by autophosphorylation of EGFR,  which 
occurs after irradiation.  Repeated irradiation of 
mammary cancer MCF-7 cells has been shown to 
result in increased TGF-alpha mRNA levels [30], 
and cleavage and extracellular release of pro-TGF-
alpha could act as a trigger for EGFR activation 
after irradiation,  with activation of factors down-
stream of EGFR [20].  Based on these reports,  it is 
of interest to determine if the combination eﬀ ects of 
an EGFR inhibitor and radiation are eﬀ ective for 
esophageal cancer,  for which radiotherapy is an 
important therapeutic approach.  The present study 
shows that an EGFR inhibitor and irradiation can 
have a synergistic eﬀ ect in esophageal cancer cells, 
although this synergistic eﬀ ect occurred in only 2 of 
the 7 cell lines investigated,  while the eﬀ ect was 
additive in the other 5 cell lines.  Diﬀ erences in the 
expression of HER family members were investigated 
in TE-3 and TE-4 cells,  in which a synergistic eﬀ ect 
was noted,  and cell lines in which an additive eﬀ ect 
occurred,  but no signiﬁ cant diﬀ erences were appar-
ent between the 2 groups.  Thus,  the cellular charac-
teristics that lead to synergism in the eﬀ ects of irra-
diation and EGFR inhibition remain unknown. 
However,  the marked synergistic eﬀ ect noted in 
TE-4 cells,  which strongly express EGFR and are 
resistant to irradiation,  is noteworthy.  Western 
blotting showed that the EGFR phosphorylation path-
way is dramatically activated after irradiation.  The 
MAPK and PI3K-Akt cascades are the pathways that 
are primarily aﬀ ected,  and these cascades were acti-
vated soon after irradiation.  Radiosensitivity 
enhancement by MAPK inhibitors has previously 
been demonstrated [3ﾝ6],  and it can therefore be 
concluded that blockage of MAPK signaling activa-
tion may be a mechanism through which the radiosen-
sitizing eﬀ ects of geﬁ tinib occur.
　　The PI3K-Akt pathway is considered to be impor-
tant as an anti-apoptotic pathway,  in which Caspase-9 
and Bad are reported to be targets of Akt ; however, 
much remains to be clariﬁ ed regarding this pathway. 
In esophageal carcinoma cell lines,  we found that the 
EGFR-PI3K-Akt pathway was activated after irradi-
ation and that geﬁ tinib inhibited its activation. 
Irradiation induced Bad phosphorylation in TE-3 
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cells,  and Bad phosphorylation was inhibited by geﬁ -
tinib.  Phosphorylation of Bad diminishes its binding 
to Bcl-xl or Bcl-2,  which is an apoptosis-induction 
factor [31],  and the PI3K-Akt pathway controls Bad 
phosphorylation and suppresses mitochondrial cyto-
chrome C release,  thereby reducing apoptosis [32, 
33].
　　In summary,  the following key points emerged 
from the present study.  The combination eﬀ ects of 
geﬁ tinib and radiotherapy in esophageal cancer cell 
lines were found to be synergistic-additive.  Inhibition 
of EGFR activation after irradiation and inhibition 
of activation of downstream death signals in the 
EGFR-MAPK and PI3K-Akt cascades by geﬁ tinib 
were considered to be the mechanisms underlying the 
synergistic eﬀ ect.  Hence,  radiotherapy combined 
with EGFR blockade may enhance the treatment 
response of esophageal carcinoma,  particularly in a 
case that is resistant to radiotherapy.
　　Geﬁ tinib has been clinically applied to lung can-
cer,  and good eﬃ  cacy of geﬁ tinib for lung cancer 
associated with EGFR mutation has recently been 
reported [29].  To facilitate the clinical application 
of geﬁ tinib in esophageal cancer,  clariﬁ cation of the 
basic relationship between the incidence and eﬀ ects 
of EGFR mutations in esophageal cancer cell lines 
and the eﬀ ects of geﬁ tinib will be of importance.
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